BR112017013999A2 - ?composição derivada de uma bifidobactéria? - Google Patents

?composição derivada de uma bifidobactéria?

Info

Publication number
BR112017013999A2
BR112017013999A2 BR112017013999-5A BR112017013999A BR112017013999A2 BR 112017013999 A2 BR112017013999 A2 BR 112017013999A2 BR 112017013999 A BR112017013999 A BR 112017013999A BR 112017013999 A2 BR112017013999 A2 BR 112017013999A2
Authority
BR
Brazil
Prior art keywords
subject
viral
bifidobacterium
composition
composition derived
Prior art date
Application number
BR112017013999-5A
Other languages
English (en)
Other versions
BR112017013999B1 (pt
Inventor
Lehtinen Markus
Lahtinen Sampo
B Turner Ronald
Original Assignee
Dupont Nutrition Biosciences Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosciences Aps filed Critical Dupont Nutrition Biosciences Aps
Publication of BR112017013999A2 publication Critical patent/BR112017013999A2/pt
Publication of BR112017013999B1 publication Critical patent/BR112017013999B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção diz respeito à composição derivável de uma bifidobactéria, métodos e usos da mesma, para a utilização na modulação do sistema imune em um sujeito afetando a ação viral e/ou efeitos virais no referido sujeito. além disso, a referida composição também pode ser usada para reduzir o risco de desenvolvimento e exacerbação de doenças respiratórias crônicas, como a asma e dpoc em um sujeito; preferencialmente modulando o sistema imune no sujeito pela capacidade de afetar a ação viral e/ou os efeitos virais no referido sujeito.
BR112017013999-5A 2015-01-27 2016-01-27 Uso de uma composição compreendendo bifidobacterium lactis BR112017013999B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562108260P 2015-01-27 2015-01-27
US62/108,260 2015-01-27
PCT/EP2016/051695 WO2016120320A1 (en) 2015-01-27 2016-01-27 Immunomodulatory composition comprising bifidobacteria

Publications (2)

Publication Number Publication Date
BR112017013999A2 true BR112017013999A2 (pt) 2018-03-13
BR112017013999B1 BR112017013999B1 (pt) 2022-05-10

Family

ID=55353174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013999-5A BR112017013999B1 (pt) 2015-01-27 2016-01-27 Uso de uma composição compreendendo bifidobacterium lactis

Country Status (12)

Country Link
US (1) US10668117B2 (pt)
EP (1) EP3250216B1 (pt)
JP (1) JP6867953B2 (pt)
KR (1) KR102442995B1 (pt)
CN (1) CN107206034A (pt)
AU (2) AU2016212100B2 (pt)
BR (1) BR112017013999B1 (pt)
CA (1) CA2969604C (pt)
DK (1) DK3250216T3 (pt)
FI (1) FI3250216T3 (pt)
RU (1) RU2755083C2 (pt)
WO (1) WO2016120320A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010143A (es) * 2017-02-28 2019-10-02 Alimentary Health Ltd Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infeccion respiratoria por virus.
CN110392734A (zh) * 2017-02-28 2019-10-29 营养健康有限公司 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌
WO2018209308A1 (en) * 2017-05-12 2018-11-15 The Regents Of The University Of California Treating and detecting dysbiosis
TWI709408B (zh) * 2018-08-16 2020-11-11 葡萄王生技股份有限公司 乳雙歧桿菌gkk2、含其之組合物及改善過敏性氣喘之用途
ES2783723A1 (es) * 2019-03-15 2020-09-17 Igen Biolab Group Ag Composicion obtenida de lisados bacterianos para modular el microbioma humano, formulacion terapeutica y suplemento alimenticio que comprenden la composicion, y usos de la composicion.
US11318174B2 (en) * 2020-07-09 2022-05-03 Dupont Nutrition Biosciences Aps Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2146935C1 (ru) 1996-04-24 2000-03-27 ЗИНЧЕНКО Владимир Борисович Сухой иммунопробиотический препарат для птицеводства
CN105288616B (zh) * 2010-10-15 2018-10-19 科.汉森有限公司 免疫佐剂
GB201110095D0 (en) * 2011-06-15 2011-07-27 Danisco Method of treatment

Also Published As

Publication number Publication date
CA2969604A1 (en) 2016-08-04
FI3250216T3 (fi) 2024-02-02
RU2755083C2 (ru) 2021-09-15
WO2016120320A1 (en) 2016-08-04
EP3250216A1 (en) 2017-12-06
AU2019200846A1 (en) 2019-02-28
RU2017129693A3 (pt) 2019-08-12
AU2016212100A1 (en) 2017-06-22
CN107206034A (zh) 2017-09-26
AU2016212100B2 (en) 2019-02-21
EP3250216B1 (en) 2023-11-08
KR20170105011A (ko) 2017-09-18
US20190099457A1 (en) 2019-04-04
US10668117B2 (en) 2020-06-02
JP6867953B2 (ja) 2021-05-12
DK3250216T3 (da) 2024-01-29
RU2017129693A (ru) 2019-03-01
CA2969604C (en) 2024-04-02
JP2018504460A (ja) 2018-02-15
BR112017013999B1 (pt) 2022-05-10
KR102442995B1 (ko) 2022-09-13

Similar Documents

Publication Publication Date Title
BR112017013999A2 (pt) ?composição derivada de uma bifidobactéria?
WO2018089851A3 (en) Influenza vaccine
BR112018070859A2 (pt) degradantes da proteína de bet
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112016006122A2 (pt) composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov)
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112016024644A2 (pt) vacinas de ácido nucleico
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112014012808A2 (pt) proteína de fusão anticâncer
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2016, OBSERVADAS AS CONDICOES LEGAIS